The veterinary office decision was challenged by an external advisory committee on animal experimentation, which argued that the proposed experiments would offend the dignity of the animals. The requirement to consider the 'dignity of creatures' was introduced into the Swiss constitution in 2004. The court did not refer to dignity, but agreed that society was unlikely to see the benefits of the research during the three-year funding period approved, and thus the burden on the animals was not justified. Swiss law requires that the benefit to society must be weighed against the burden to animals before any animal experiment can take place. “But the court has made a new interpretation of the law which demands immediate benefits — and that's not compatible with any form of basic research,” says Peter Chen, vice-president for research at ETHZ. “It goes beyond the requirement of the law and we have no choice but to contest the decision in the highest court.”
The experiments were to be done at the Institute of Neuroinformatics, jointly owned by the two institutes. One experiment, to monitor changes in the cortex during perceptual learning, involved denying test monkeys a drink for up to twelve hours to increase the value of the apple juice reward they would be offered if they learnt a new task correctly. The other experiment, designed to understand the microcircuitry in the cortex, involved sacrificing the animals to follow the microcircuitry microscopically. The scientists use primates because their brains are closer to the human brain than any other species. “We need to understand the basic biology of our brains in order to be able to successfully treat brain diseases such as Parkinson's,” says Kevan Martin, one of the researchers. He says he intends to re-apply for ethics approval, making the value of the research more explicit. Roger Lemon, a neuroscientist at University College London, UK, says that finding out how brain circuitry works in normal as well as disease conditions is fundamental if new therapies are to be developed for neurological disorders. “A huge amount of the sort of work that Martin and his colleagues do lies behind the breakthroughs in applications we are now starting to see.”
Nature
June 24, 2008
Original web page at Nature



